• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

胶原蛋白合成酶P4HA3作为一种新型的结直肠癌生物标志物，与预后和免疫浸润相关。

Collagen synthase P4HA3 as a novel biomarker for colorectal cancer correlates with prognosis and immune infiltration.

作者信息

Guo Xiaohuan, Zhang Yu, Peng Lina, Wang Yaling, He Cheng-Wen, Li Kaixuan, Hao Ke, Li Kaiqiang, Wang Zhen, Huang Haishan, Miao Xiaolin

机构信息

School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, 325035, China.

Department of Gastroenterology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, 310014, China.

出版信息

Heliyon. 2024 May 22;10(11):e31695. doi: 10.1016/j.heliyon.2024.e31695. eCollection 2024 Jun 15.

DOI:10.1016/j.heliyon.2024.e31695
PMID:38832271
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11145334/
Abstract

OBJECTIVE

In this study, we aimed to determine whether proly4-hydroxylase-III (P4HA3) could be used as a biomarker for the diagnosis of colorectal cancer (CRC) as well as for determining prognosis.

METHODS

We used The Cancer Genome Atlas (TCGA) database to analyze P4HA3 expression in CRC and further investigated the association between P4HA3 and clinicopathological parameters, immune infiltration, and prognosis of patients with CRC. Enrichment analysis was conducted to investigate the potential biological role of P4HA3 in CRC. To verify the results of TCGA analysis, we performed immunohistochemical staining of 180 clinical CRC tissue samples to probe into the relationship of P4HA3 expression with lymphocyte infiltration and immune checkpoints expression.

RESULTS

The expression of P4HA3 was significantly higher in CRC tissues and associated with a higher degree of malignancy and poorer prognosis in CRC. The results of enrichment analysis indicated that P4HA3 may be associated with the epithelial-mesenchymal transition process and the immune response. Immunohistochemical staining results showed that high P4HA3 expression was associated with high infiltration levels of CD8 and Foxp3+ TILs and high PD-1/PD- L1 expression. Lastly, patients with CRC co-expressing P4HA3 and PD-1 had a significantly worse prognosis.

CONCLUSION

High expression of P4HA3 is associated with adverse clinical features and immune cell infiltration in CRC, and has the potential to serve as a biomarker for predicting CRC prognosis.

摘要

目的

在本研究中，我们旨在确定脯氨酰4-羟化酶III（P4HA3）是否可作为诊断结直肠癌（CRC）以及判断预后的生物标志物。

方法

我们使用癌症基因组图谱（TCGA）数据库分析CRC中P4HA3的表达，并进一步研究P4HA3与CRC患者的临床病理参数、免疫浸润和预后之间的关联。进行富集分析以研究P4HA3在CRC中的潜在生物学作用。为了验证TCGA分析的结果，我们对180例临床CRC组织样本进行免疫组织化学染色，以探究P4HA3表达与淋巴细胞浸润及免疫检查点表达之间的关系。

结果

P4HA3在CRC组织中的表达显著更高，且与CRC的更高恶性程度和更差预后相关。富集分析结果表明，P4HA3可能与上皮-间质转化过程和免疫反应有关。免疫组织化学染色结果显示，P4HA3高表达与CD8和Foxp3 +肿瘤浸润淋巴细胞（TILs）的高浸润水平以及高PD-1/PD-L1表达相关。最后，共表达P4HA3和PD-1的CRC患者预后明显更差。

结论

P4HA3的高表达与CRC的不良临床特征和免疫细胞浸润相关，并且有潜力作为预测CRC预后的生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9dcc/11145334/226ffb4a209c/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9dcc/11145334/fc9aff02befd/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9dcc/11145334/ecae1eac3322/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9dcc/11145334/db5e926e0db2/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9dcc/11145334/f101de32df58/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9dcc/11145334/d8479dcfec2d/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9dcc/11145334/226ffb4a209c/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9dcc/11145334/fc9aff02befd/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9dcc/11145334/ecae1eac3322/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9dcc/11145334/db5e926e0db2/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9dcc/11145334/f101de32df58/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9dcc/11145334/d8479dcfec2d/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9dcc/11145334/226ffb4a209c/gr6.jpg

相似文献

1
Collagen synthase P4HA3 as a novel biomarker for colorectal cancer correlates with prognosis and immune infiltration.胶原蛋白合成酶P4HA3作为一种新型的结直肠癌生物标志物，与预后和免疫浸润相关。
Heliyon. 2024 May 22;10(11):e31695. doi: 10.1016/j.heliyon.2024.e31695. eCollection 2024 Jun 15.
2
Systematic pan-cancer analysis of the potential tumor diagnosis and prognosis biomarker P4HA3.潜在肿瘤诊断和预后生物标志物P4HA3的全癌系统分析
Front Genet. 2023 Mar 22;14:1045061. doi: 10.3389/fgene.2023.1045061. eCollection 2023.
3
High Prolyl 4-Hydroxylase Subunit Alpha 3 Expression as an Independent Prognostic Biomarker and Correlated With Immune Infiltration in Gastric Cancer.高脯氨酰4-羟化酶α3亚基表达作为胃癌独立的预后生物标志物及其与免疫浸润的相关性
Front Genet. 2022 Jul 1;13:952335. doi: 10.3389/fgene.2022.952335. eCollection 2022.
4
Prognostic Value and Immunological Role of P4HA3 in Colon Adenocarcinoma.P4HA3在结肠腺癌中的预后价值及免疫作用
Int J Gen Med. 2023 May 23;16:1953-1971. doi: 10.2147/IJGM.S407068. eCollection 2023.
5
Comprehensive analysis reveals that P4HA3 is a prognostic and diagnostic gastric cancer biomarker that can predict immunotherapy efficacy.综合分析表明，P4HA3 是一种预后和诊断胃癌的生物标志物，可预测免疫治疗疗效。
Sci Rep. 2024 Oct 3;14(1):22959. doi: 10.1038/s41598-024-73784-z.
6
Mapk14 is a Prognostic Biomarker and Correlates with the Clinicopathological Features and Immune Infiltration of Colorectal Cancer.丝裂原活化蛋白激酶14是一种预后生物标志物，与结直肠癌的临床病理特征和免疫浸润相关。
Front Cell Dev Biol. 2022 Jan 24;10:817800. doi: 10.3389/fcell.2022.817800. eCollection 2022.
7
Tumor microenvironment-related gene selenium-binding protein 1 (SELENBP1) is associated with immunotherapy efficacy and survival in colorectal cancer.肿瘤微环境相关基因硒结合蛋白 1（SELENBP1）与结直肠癌的免疫治疗疗效和生存相关。
BMC Gastroenterol. 2022 Oct 17;22(1):437. doi: 10.1186/s12876-022-02532-2.
8
ATP6AP1 as a potential prognostic biomarker in CRC by comprehensive analysis and verification.通过综合分析和验证，ATP6AP1 作为 CRC 的潜在预后生物标志物。
Sci Rep. 2024 Feb 18;14(1):4018. doi: 10.1038/s41598-024-54437-7.
9
CILP2: A prognostic biomarker associated with immune infiltration in colorectal cancer.CILP2：一种与结直肠癌免疫浸润相关的预后生物标志物。
Heliyon. 2023 Apr 20;9(5):e15535. doi: 10.1016/j.heliyon.2023.e15535. eCollection 2023 May.
10
CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer.CMTM6 与 PD-L1 的共表达与结直肠癌中活跃的免疫微环境和良好的预后相关。
J Immunother Cancer. 2021 Feb;9(2). doi: 10.1136/jitc-2020-001638.

本文引用的文献

1
Systematic pan-cancer analysis of the potential tumor diagnosis and prognosis biomarker P4HA3.潜在肿瘤诊断和预后生物标志物P4HA3的全癌系统分析
Front Genet. 2023 Mar 22;14:1045061. doi: 10.3389/fgene.2023.1045061. eCollection 2023.
2
P4HA3 promotes clear cell renal cell carcinoma progression via the PI3K/AKT/GSK3β pathway.P4HA3通过PI3K/AKT/GSK3β信号通路促进肾透明细胞癌进展。
Med Oncol. 2023 Jan 2;40(2):70. doi: 10.1007/s12032-022-01926-2.
3
High Prolyl 4-Hydroxylase Subunit Alpha 3 Expression as an Independent Prognostic Biomarker and Correlated With Immune Infiltration in Gastric Cancer.
高脯氨酰4-羟化酶α3亚基表达作为胃癌独立的预后生物标志物及其与免疫浸润的相关性
Front Genet. 2022 Jul 1;13:952335. doi: 10.3389/fgene.2022.952335. eCollection 2022.
4
Prolyl 4-hydroxylase subunit alpha 3 facilitates human colon cancer growth and metastasis through the TGF-β/Smad signaling pathway.脯氨酰 4-羟化酶亚基α3通过TGF-β/Smad信号通路促进人结肠癌的生长和转移。
Pathol Res Pract. 2022 Feb;230:153749. doi: 10.1016/j.prp.2021.153749. Epub 2021 Dec 24.
5
A deep learning quantified stroma-immune score to predict survival of patients with stage II-III colorectal cancer.一种用于预测II-III期结直肠癌患者生存率的深度学习量化基质-免疫评分。
Cancer Cell Int. 2021 Oct 30;21(1):585. doi: 10.1186/s12935-021-02297-w.
6
YTHDF1 and YTHDF2 are associated with better patient survival and an inflamed tumor-immune microenvironment in non-small-cell lung cancer.YTHDF1 和 YTHDF2 与非小细胞肺癌患者更好的生存和炎症肿瘤免疫微环境相关。
Oncoimmunology. 2021 Aug 10;10(1):1962656. doi: 10.1080/2162402X.2021.1962656. eCollection 2021.
7
Global colorectal cancer burden in 2020 and projections to 2040.2020年全球结直肠癌负担及到2040年的预测。
Transl Oncol. 2021 Oct;14(10):101174. doi: 10.1016/j.tranon.2021.101174. Epub 2021 Jul 6.
8
TGF-β-dependent reprogramming of amino acid metabolism induces epithelial-mesenchymal transition in non-small cell lung cancers.TGF-β 依赖性氨基酸代谢重编程诱导非小细胞肺癌中的上皮-间充质转化。
Commun Biol. 2021 Jun 24;4(1):782. doi: 10.1038/s42003-021-02323-7.
9
Type I collagen deletion in αSMA myofibroblasts augments immune suppression and accelerates progression of pancreatic cancer.Ⅰ型胶原在 αSMA 肌成纤维细胞中的缺失增强了免疫抑制作用，并加速了胰腺癌的进展。
Cancer Cell. 2021 Apr 12;39(4):548-565.e6. doi: 10.1016/j.ccell.2021.02.007. Epub 2021 Mar 4.
10
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020：全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.